Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapy

Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapy - Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016639

Enrollment

100

Registered

2015-02-26

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

IL28B gene major and relapse of previous treatment/first treatment patient with intrahepatic IFN stimulating gene index&lt

3.5: 12 week Peg-IFN-alfa2b/Ribavirin/Vaniprevir therapy following 12week Peg-IFN-alfa 2b/Ribavirin therapy IL28B gene major and first treatment patient with intrahepatic IFN stimulating gene index 3.

3.5: 12 week Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy following 12week Peg-IFN-alfa2b/Ribavirin therapy IL28B gene minor and relapse of previous treatment/first treatment patient with intrahepatic

3.5: 12 week Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy following 36 week Peg-IFN-alfa 2b/Ribavirin therapy IL28B gene minor and first treatment patient with intrahepatic IFN stimulating gene index

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C serogroup1

Exclusion criteria

Exclusion criteria: contraindication of Peg-IFN/Ribavirin/Vaniprevir therapy

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactTetsuro Shimakami

Kanazawa University Hospital Department of Gastrotenterology

shimakami@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026